Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2024 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
October 08, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 02, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
August 13, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
July 22, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
June 03, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
May 15, 2024 07:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 14, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 02, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma announces first quarter 2024 results and provides corporate update
March 22, 2024 04:00 ET | Source: Molecure

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...